Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

about

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

Item

http://www.wikidata.org/entity/Q36356624

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

@ast

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

@en

type

Item

label

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

@ast

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

@en

prefLabel

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

@ast

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.

@en

P1476

Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study

@en

P2093

Abdulla Shehab

http://www.w3.org/2001/XMLSchema#string

Adel Sadik

http://www.w3.org/2001/XMLSchema#string

Aesha Al Suwaidi

http://www.w3.org/2001/XMLSchema#string

Ali AlShamsi

http://www.w3.org/2001/XMLSchema#string

Farah Hamad

http://www.w3.org/2001/XMLSchema#string

Mahmoud Abu Mandil

http://www.w3.org/2001/XMLSchema#string

Pinar Erkekoglu

http://www.w3.org/2001/XMLSchema#string

Saif K Al Nuaimi

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran: how the drug company withheld important analyses

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Edoxaban versus warfarin in patients with atrial fibrillation

Dabigatran, bleeding, and the regulators

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

P304

1290-1298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15537/SMJ.2015.11.12154

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Akshaya Srikanth Bhagavathula

A A Elnour

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284516417

http://www.w3.org/2001/XMLSchema#string

P698

26593161

http://www.w3.org/2001/XMLSchema#string

P932

4673365

http://www.w3.org/2001/XMLSchema#string